Structure-based classification predicts drug response in EGFR-mutant NSCLC

Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18–21 and are established driver mutations in non-small cell lung cancer (NSCLC)(1–3). Targeted therapies are approved for patients with ‘classical’ mutations and a small number of other mutations(4–6). However, effective the...

Descripción completa

Detalles Bibliográficos
Autores principales: Robichaux, Jacqulyne P., Le, Xiuning, Vijayan, R. S. K., Hicks, J. Kevin, Heeke, Simon, Elamin, Yasir Y., Lin, Heather Y., Udagawa, Hibiki, Skoulidis, Ferdinandos, Tran, Hai, Varghese, Susan, He, Junqin, Zhang, Fahao, Nilsson, Monique B., Hu, Lemei, Poteete, Alissa, Rinsurongkawong, Waree, Zhang, Xiaoshan, Ren, Chenghui, Liu, Xiaoke, Hong, Lingzhi, Zhang, Jianjun, Diao, Lixia, Madison, Russell, Schrock, Alexa B., Saam, Jennifer, Raymond, Victoria, Fang, Bingliang, Wang, Jing, Ha, Min Jin, Cross, Jason B., Gray, Jhanelle E., Heymach, John V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481125/
https://www.ncbi.nlm.nih.gov/pubmed/34526717
http://dx.doi.org/10.1038/s41586-021-03898-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8481125/
https://www.ncbi.nlm.nih.gov/pubmed/34526717
http://dx.doi.org/10.1038/s41586-021-03898-1

Ejemplares similares